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Heart failure (HF), the leading cause of death in the western world, ensues in response
to cardiac injury or insult and represents the inability of the heart to adequately pump
blood and maintain tissue perfusion. It is characterized by complex interactions of several
neurohormonal mechanisms that get activated in the syndrome in order to try and sustain
cardiac output in the face of decompensating function. The most prominent among these
neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS),
whose activity and outflow are greatly elevated in HF. Acutely, provided that the heart still
works properly, this activation of the ANS will promptly restore cardiac function according
to the fundamental Frank-Starling law of cardiac function. However, if the cardiac insult
persists over time, this law no longer applies and ANS will not be able to sustain cardiac
function. This is called decompensated HF, and the hyperactive ANS will continue to
“push” the heart to work at a level much higher than the cardiac muscle can handle. From
that point on, ANS hyperactivity becomes a major problem in HF, conferring significant
toxicity to the failing heart and markedly increasing its morbidity and mortality. The present
review discusses the role of the ANS in cardiac physiology and in HF pathophysiology,
the mechanisms of regulation of ANS activity and how they go awry in chronic HF, and,
finally, the molecular alterations in heart physiology that occur in HF along with their
pharmacological and therapeutic implications for the failing heart.
Keywords: adrenergic nervous system, heart failure, cardiac myocyte, adrenal gland, catecholamine, adrenergic
receptor
INTRODUCTION
Heart failure (HF) is a clinical syndrome that develops in response
to a cardiac injury or insult that causes decline in the pumping
capacity (contractile function) of the heart. It is marked by a per-
petual interplay between the underlying myocardial dysfunction
and the compensatory neurohumoral mechanisms that are acti-
vated in an effort to maintain cardiac output in the face of declin-
ing heart function. Among these neurohormonal mechanisms,
elevated activities of the adrenergic (or sympathetic) nervous sys-
tem (ANS), of the renin-angiotensin-aldosterone system (RAAS),
and of several cytokines, play central roles (Mann and Bristow,
2005; Mudd and Kass, 2008). These systems get activated in an
effort to compensate for the depressed myocardial function and
preserve cardiovascular homeostasis. Upon long-term presence of
the initial insult to the heart muscle, however, cardiac function
ultimately succumbs to their deleterious effects on cardiac struc-
ture and performance, leading to cardiac decompensation, and
this progressively worsening function renders the heart unable to
sustain daily life activities. The present review will discuss the role
of the ANS in cardiac physiology and pathophysiology.
ANS AND CARDIAC FUNCTION
The ANS exerts a wide variety of cardiovascular effects, includ-
ing heart rate acceleration (positive chronotropy), increase in
cardiac contractility (positive inotropy), accelerated cardiac relax-
ation (positive lusitropy), accelerated atrioventricular conduction
(positive dromotropy), decrease in venous capacitance, and con-
striction of resistance and cutaneous vessels (Figure 1). All of
these effects aim to increase cardiac performance to prepare
and enable the body for the so-called “fight or flight response.”
Conversely, the mirror branch of the autonomic nervous sys-
tem, the parasympathetic (cholinergic) nervous system, slows
the heart rate (bradycardia) through vagal nerve impulses, with
minimal or no effect on cardiac contractility. This is because
the cardiac ventricles, responsible for contraction, receive almost
exclusively adrenergic fiber innervations, whereas the choliner-
gic system fibers run with the vagus nerve subendocardially,
after it crosses the atrioventricular groove, and reach mainly the
atrial myocardium with minimal connections to the ventricular
myocardium (Zipes, 2008; Triposkiadis et al., 2009). Therefore,
whereas heart rate can be controlled (in opposing fashion) by
both autonomic branches, cardiac contraction/relaxation is con-
trolled practically solely by the ANS (Figure 1).
The ventricular ANS innervation is characterized by a gradient
from base to apex (Pierpont et al., 1985). The cardiac neuronal
system is composed of cell stations comprising afferent, effer-
ent, and interconnecting neurons behaving as a control system
(Armour, 2004). The ANS outflow to the heart and to the periph-
eral circulation is regulated by cardiovascular reflexes. Afferent
fibers project to the central nervous system by the autonomic
nerves, whereas efferent impulses travel from the central nervous
system to peripheral organs. The main reflex responses originate
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FIGURE 1 | Overview of the cardiovascular ANS. In contrast to the ANS
which innervates both atria and ventricles of the heart, the cholinergic
(parasympathetic) nervous system mainly innervates cardiac atria only. See
text for more details. CSAR, cardiac sympathetic afferent reflex; H,
hypothalamus; M, medulla oblongata.
from the aortic arch and the carotid baroreceptors (ANS inhibi-
tion), cardiopulmonary baroreceptors (diverse reflexes including
the Bezold-Jarisch reflex, ANS inhibition), cardiovascular low-
threshold polymodal receptors (ANS activation), and periph-
eral chemoreceptors (ANS activation) (Malliani et al., 1983;
Triposkiadis et al., 2009).
ANS activation in the cardiovascular system translates into
release of the two catecholamines that mediate its effects, i.e.,
norepinephrine (NE or noradrenaline) and epinephrine (Epi or
adrenaline), and this can occur via the following mechanisms
(Figure 2): (a) NE released by cardiac sympathetic nerve ter-
minals, resulting in an increase in heart rate and shortening
of atrioventricular conduction, and in an increase in contrac-
tile strength, (b) Epi (and to a much lesser extent NE) released
into the circulation by the adrenal medulla, affecting both the
myocardium and peripheral vessels, and, finally, (c) local release
of NE and Epi by various peripheral adrenergic nervous sys-
tems that can synthesize and release these catecholamines in
an autocrine/paracrine manner and are located in blood vessels
and in cardiac myocytes themselves (Lymperopoulos et al., 2007,
2012).
ADRENERGIC RECEPTORS (ARs) IN THE CARDIOVASCULAR SYSTEM
The ANS neurotransmitters NE and Epi mediate their effects
in cells and tissues by binding to specific cell surface ARs,
which belong to the superfamily of G protein-coupled receptors
(GPCRs) or seven transmembrane-spanning receptors or hepta-
helical receptors (7TMRs). Approximately 80% of NE released by
ANS nerve terminals is recycled by the NE transporter (NET)
type 1, whereas the remainder spills over into the circulation
(Leineweber et al., 2002). The receptors for both ANS cate-
cholamines are divided into three types and 9 total different sub-
types, as follows: three α1AR subtypes (α1A, α1B, α1D), three α2AR
subtypes (α2A, α2B, α2C), and three βAR subtypes (β1, β2, β3)
FIGURE 2 | ANS-dependent regulation of cardiac function. See text for
details. Gi/o, inhibitory or other G protein; Gs, stimulatory G protein; Ach,
Acetylcholine; NET, NE transporter; Aldo, Aldosterone; MR,
Mineralocorticoid Receptor.
(Bylund et al., 1994). All ARs primarily signal through het-
erotrimeric G proteins. The human heart contains all three βAR
subtypes (Lymperopoulos et al., 2012). β1AR is the predominant
subtype in the (normal, healthy) myocardium, representing 75–
80% of total βAR density, followed by β2AR, which comprises
about 15–18% of total cardiomyocyte βARs and the remaining
2–3% is β3ARs (under normal conditions) (Brodde, 1993). The
principal role of βARs in the heart is the regulation of cardiac
rate and contractility in response to NE and Epi. Stimulation of
β1ARs (mainly) and of β2ARs (to a lesser extent) increases car-
diac contractility (positive inotropic effect), frequency (positive
chronotropic effect), and rate of relaxation (lusitropic effect) as
well as accelerates impulse conduction through the atrioventric-
ular node (positive dromotropic effect) and pacemaker activity
from the sinoatrial node (Colucci et al., 1986). β3ARs are predom-
inantly inactive during normal physiologic conditions (Skeberdis
et al., 2008); however, their stimulation seems to produce a nega-
tive inotropic effect opposite to that induced by β1ARs and β2ARs,
involving the nitric oxide synthase (NOS) pathway (Gauthier
et al., 1998), thus acting as a “fuse” against cardiac adrenergic
overstimulation (Rozec et al., 2009). Agonist-induced activa-
tion of βARs catalyzes the exchange of guanosine triphosphate
(GTP) for guanosine diphosphate (GDP) on the Gα subunit of
heterotrimeric G proteins, resulting in the dissociation of the het-
erotrimer into active Gα and free Gβγ subunits (always associated
together, i.e., a heterodimer that functions as a monomer) which
can transduce intracellular signals independently of each other
(Lohse et al., 2003). The most powerful physiologic mechanism
to increase cardiac performance is activation of cardiomyocyte
β1ARs and β2ARs, which, in turn, activates Gs proteins (stim-
ulatory G proteins). Gs protein signaling stimulates the effector
adenylate cyclase (AC), which converts adenosine triphosphate
(ATP) to the second messenger adenosine 3′,5′-monophosphate
or cyclic AMP (cAMP), which in turn binds to and activates
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the cAMP-dependent protein kinase (protein kinase A, PKA).
PKA is the major effector of cAMP (there is also Epac, exchange
protein directly activated by cAMP, which can be activated by
cAMP independently of PKA and whose precise roles in the
heart are currently unknown), and, by phosphorylating a variety
of substrates, including plasmalemmal L-type calcium channels
and the sarco/endoplasmic reticulum calcium ATPase regulator
phospholamban, it ultimately results in significant raise in free
intracellular Ca2+ concentration, which is the master regulator of
cardiac muscle contraction
Of note, β2AR also mediates the effects of catecholamines in
the heart, but in a qualitatively different manner from β1AR, as it
can also couple to the AC inhibitory G protein (Gi). In fact, this
switching of β2AR signaling from Gs to Gi proteins is postulated
to be induced by the phosphorylation of the β2AR by PKA (Daaka
et al., 1997). Nonetheless, it is now generally accepted that in the
heart, β2AR signals and functions in a substantially different way
compared to β1AR (Communal et al., 1999; Chesley et al., 2000;
Zhu et al., 2001). Importantly, whereas β1AR activation enhances
cardiomyocyte apoptosis, β2AR exerts antiapoptotic effects in the
heart (Communal et al., 1999; Dorn et al., 1999; Chesley et al.,
2000; Zhu et al., 2001). This essential difference between the two
receptor subtypes is ascribed to the signal of β2AR through Gi
proteins (Chesley et al., 2000). Studies using transgenic mice,
β2AR-selective stimulation and adenoviral-mediated β2AR over-
expression, have demonstrated the protective effects of β2AR
signaling in the myocardium, including improved cardiac func-
tion and decreased apoptosis. Conversely, hyperstimulation or
overexpression of β1AR has detrimental effects in the heart (Dorn
et al., 1999; Liggett et al., 2000).
Both α2- and βARs, like the majority of GPCRs, are subject to
agonist-promoted (homologous) desensitization and downreg-
ulation, a regulatory process that diminishes receptor response
to continuous or repeated agonist stimulation (Ferguson, 2001;
Reiter and Lefkowitz, 2006). At the molecular level, this process
is initiated by receptor phosphorylation by a family of kinases,
termed GPCR kinases (GRKs), followed by binding of βarrestins
(βarrs) to the GRK-phosphorylated receptor (see below). The
βarrs then uncouple the receptor from its cognate G proteins,
sterically hinder its further binding to them (functional desensiti-
zation) and subsequently target the receptor for internalization
(Ferguson, 2001; Reiter and Lefkowitz, 2006). Across all mam-
malian species, GRK2 and GRK5 are the most physiologically
important members of the GRK family because they are expressed
ubiquitously and regulate the vast majority of GPCRs. They are
particularly abundant in neuronal tissues and in the heart (Arriza
et al., 1992; Rockman et al., 2002).
Of note, the differences between the two predominant cardiac
βARs, i.e., β1AR & β2AR, in terms of their signaling properties,
might take a quite different shape and have a much bigger bear-
ing on pathophysiologic implications in the setting of human HF:
for instance, and as discussed in more detail in subsequent sec-
tions, β1AR is selectively downregulated (i.e., functional receptor
number reduced) in human HF, thus shifting the above men-
tioned stoichiometry of β1AR:β2AR toward 50:50 in the failing
heart from ∼75:∼20% in the normal, healthy heart (Bristow
et al., 1982, 1986). However, β2AR is also non-functional and
does not signal properly in the failing heart (Bristow et al., 1982,
1986; Rockman et al., 2002). In addition, emerging evidence
suggests that β2AR signaling in the failing heart is quite dif-
ferent from that in the normal heart, i.e., is more diffuse and
non-compartmentalized and resembles more the pro-apoptotic
“diffuse” cAMP signaling pattern of the β1AR (Nikolaev et al.,
2010). Therefore, this stoichiometric shift in favor of the suppos-
edly “good” β2AR inHF appears unable to help the heart improve
its structure and function.
The human heart also expresses α1A- and α1BARs, albeit at
much lower levels than βARs (∼20% of total βARs) (Woodcock
et al., 2008). The importance of cardiac α1ARs in cardiac physiol-
ogy is still a matter of debate. In contrast, their role in regulation
of blood flow by inducing constriction in the smooth muscle
wall of major arteries (e.g., aorta, pulmonary arteries, mesenteric
vessels, coronary arteries, etc.) is well known and indisputable
(Shannon and Chaudhry, 2006). The α1ARs couple to the Gq/11
family of heterotrimeric G proteins, thereby activating phospho-
lipase C (PLC)-β. PLCβ generates the second messengers inosi-
tol [1,4,5]-trisphosphate (IP3) and 2-diacylglycerol (DAG) from
the cell membrane component phospholipid phosphatidylinosi-
tol (Pierpont et al., 1985; Triposkiadis et al., 2009)-bisphosphate
(PIP2). IP3 binds specific receptors in the SR membrane which
cause release of Ca2+ from intracellular stores, whereas DAG
activates protein kinase C (PKC) and transient receptor poten-
tial (TRPV) channels. The end result is again raised intracellular
[Ca2+], which leads to contraction (vasoconstriction).
Finally, regarding α2AR subtypes, α2BARs are known to be
present in vascular smooth muscle causing constriction of certain
vascular beds, while centrally located α2AARs can inhibit sym-
pathetic outflow (presynaptic inhibitory autoreceptors) and thus
lower systemic blood pressure (Philipp et al., 2002; Philipp and
Hein, 2004). The release of NE from cardiac sympathetic nerve
terminals is controlled by both presynaptic α2A- and α2CARs
(Hein et al., 1999), and genetic deletion of both of these α2AR
subtypes leads to cardiac hypertrophy and HF due to chroni-
cally enhanced cardiac NE release, as well as enhanced NE and
Epi secretion from the adrenal medulla (Brede et al., 2002, 2003;
Lymperopoulos et al., 2007).
REGULATION OF ANS OUTFLOW & ACTIVITY IN HEALTH AND IN
CHRONIC HF
There are several mechanisms by which the ANS controls cardiac
function. The first one to be documented historically is through
the aortic arch and carotid sinus (high pressure) and cardiopul-
monary (low pressure) baroreceptor reflexes (Kaye and Esler,
2005). Aside from these baroreceptor inputs, additional factors
that act within the central nervous system play a role in regula-
tion of cardiac ANS activity. In particular, suprabulbar subcor-
tical monoaminergic neurons and brainstem angiotensin II have
attracted interest courtesy of their ability to regulate ANS out-
flow in HF (Figure 2). NE turnover in subcortical regions in HF
is significantly higher than that in the cortex and than in healthy
subjects (Aggarwal et al., 2002). Moreover, the rate of subcortical
NE release correlates well with global ANS activity, as measured
by total body NE plasma spillover. Angiotensin II-dependent
ANS activation plays an important role in adverse hemodynamic
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and left ventricular remodeling responses to myocardial infarc-
tion, possibly through superoxide formation (Lindley et al., 2004;
Wang et al., 2004). Thus, part of the benefit of RAAS modulators
in HF might derive from centrally-mediated suppression of ANS
activity.
As the heart becomes progressively unresponsive to the stim-
ulatory effects of catecholamines, chronic stimulation of cardiac
ANS nerve terminals leads to chronically elevated NE release in
the heart (increased NE spillover). Presynaptic α2ARs present on
cardiac ANS nerve terminals and acting as NE release-inhibiting
autoreceptors play a crucial role in regulation of cardiac NE
release from sympathetic nerves (Philipp et al., 2002; Philipp and
Hein, 2004). Indeed, knockout (KO) mice lacking either the α2A-
or α2CAR subtype show significantly enhanced cardiac ANS activ-
ity and circulating catecholamine levels, as well as significantly
worse heart function and clinical indices, during the course of
surgical pressure overload (bymeans of transverse aortic constric-
tion, TAC)-induced HF compared with age-matched wild-type
HF mice (Hein et al., 1999; Brede et al., 2002). Moreover, dou-
ble α2A/α2CAR KO mice exhibit even worse cardiac phenotypes
than single α2AAR KO mice and, by 4 months of age, they spon-
taneously develop cardiomyopathy (without stress or any specific
insult) (Brum et al., 2002). In HF patients, the expected inhibitory
effects of α2AR stimulation on NE spillover are markedly blunted,
thereby contributing to the increase in cardiac NE spillover
observed in chronic HF (Aggarwal et al., 2001). Thus, presy-
naptic inhibitory α2-adrenergic autoreceptors crucially regulate
ANS cardiac nerve activity and NE release into the heart and
any dysfunction of these receptors either due to genetic polymor-
phisms or enhanced desensitization/downregulation (see below)
translate into increased morbidity and mortality in chronic HF
(Figure 2). Perhaps the crucial role of presynaptic α2ARs in reg-
ulating NE release from cardiac ANS nerves stems from the fact
that they are the only presynaptic ARs that can inhibit NE release;
presynaptic βARs (of the β2AR subtype, mainly) are facilitatory
autoreceptors enhancing NE release at sympathetic nerve ter-
minals (Docherty, 2002), a phenomenon whose inhibition may
contribute to the therapeutic benefit of β-blockers in HF (see
below) (Figure 2).
Circulating Epi and NE derive from two major sources
in the body: the cardiac sympathetic nerve endings, which
release NE directly onto the cardiac muscle, and the adrenal
medulla, whose chromaffin cells synthesize, store and release Epi
(mainly) and NE upon acetylcholine stimulation of the nico-
tinic cholinergic receptors (nAChRs) present on their cell mem-
branes (Figure 2; Lymperopoulos et al., 2007). Epi represents
approximately 80% of the total adrenal catecholamine secretion
under normal conditions, with NE the rest ∼20% (Eaton and
Duplan, 2004). However, these percentages vary widely depend-
ing on the physiological condition of the adrenal gland and
of the whole body. Thus, all of the Epi in the body and a
significant amount of circulating NE derive from the adrenal
medulla, and the total amount of catecholamines presented to
cardiac ARs at any given time is composed of these circulat-
ing NE & Epi plus NE released locally from sympathetic nerve
terminals within the heart (Lymperopoulos et al., 2007). The
secretion of catecholamines from the adrenal glands is regulated
in a complex manner by a variety of cell membrane recep-
tors present in chromaffin cells. Many of these receptors are
GPCRs, including, similarly to cardiac ANS nerve endings, α2ARs
that inhibit secretion (inhibitory presynaptic autoreceptors), and
βARs that enhance it (facilitatory presynaptic autoreceptors)
(Figure 2; Hein et al., 1999; Brede et al., 2002; Philipp and
Hein, 2004; Lymperopoulos et al., 2007). Of note, although var-
ious presynaptic auto- and heteroreceptors, facilitate (increase)
adrenal catecholamine secretion, e.g., βARs, muscarinic cholin-
ergic receptors (mAChRs), angiotensin II-ergic, histaminergic,
and adrenomedullin receptors, the α2ARs are the only receptor
type reported to date to inhibit adrenal catecholamine secretion
(Brede et al., 2003; Moura et al., 2006; Lymperopoulos et al.,
2007).
An increase in GRK2 expression and activity (see above) has
been documented in several cardiovascular diseases, including
increased cardiac expression in HF (Rengo et al., 2011, 2012a;
Lymperopoulos and Bathgate, 2012) and increased expression in
some vascular beds in hypertension (Penn et al., 2000). Recently,
we reported that GRK2 expression and activity are increased
also in the adrenal medulla during HF (Lymperopoulos et al.,
2007). Specifically, our studies over the past few years have
established that adrenal GRK2 upregulation is responsible for
severe adrenal α2AR dysfunction in chronic HF, which causes
a loss of the sympathoinhibitory function of these receptors in
the adrenal gland, and catecholamine secretion is thus chroni-
cally elevated (Figure 2; Lymperopoulos et al., 2007, 2008, 2010;
Rengo et al., 2010, 2012b). This emerging crucial role for adrenal
GRK2 in HF is underlined by the fact that its specific inhi-
bition, via adenoviral-mediated βARKct adrenal gene delivery,
leads to a significant reduction in circulating catecholamine lev-
els, restoring not only adrenal, but also cardiac function in HF
(Lymperopoulos et al., 2007). Additional evidence for the crucial
role of adrenal GRK2-regulated α2ARs in regulating adrenal ANS
tone in HF comes from the phenylethanolamine-N-methyl trans-
ferase (PNMT)-driven GRK2 KO mice (Lymperopoulos et al.,
2010). These mice, which do not express GRK2 in their adrenal
medullae from birth, display decreased ANS outflow and cir-
culating catecholamines in response to myocardial infarction,
which translates into preserved cardiac function and morphol-
ogy over the course of the ensuing HF (Lymperopoulos et al.,
2010). Of note, elevated GRK2-dependent α2AR dysfunction dur-
ing HF might also occur in other peripheral sympathetic nerve
terminals of the heart (Figure 2) and of other organs, thus con-
tributing to the increased NE release and spillover, as well as
to the presynaptic α2AR dysfunction in ANS neurons observed
in chronic HF (see above) (Lang et al., 1997; Aggarwal et al.,
2001).
EFFECTS OF ANS OVERACTIVITY IN CHRONIC HF
Myocardial systolic dysfunction is associated with neurohor-
monal hyperactivity as a compensatory mechanism to maintain
cardiac output in the face of declining cardiac function. The neu-
ronal part of this response is represented by ANS cardiac nerve
terminals, whereas the hormonal (or humoral) part is represented
by increased secretion, and elevated circulating levels of certain
hormones, the most prominent being Epi & NE, along with
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the RAAS hormones (i.e., angiotensin II & aldosterone) (Dzau
et al., 1981). ANS hyperactivity is evidenced by increased plasma
NE & Epi levels, elevated (central) sympathetic outflow, and
heightened NE spillover from activated cardiac sympathetic nerve
terminals into the circulation (Pepper and Lee, 1999). Cardiac
NE spillover in untreated HF patients can reach up to 50-fold
higher levels than those of healthy individuals under maximal
exercise conditions (Morris et al., 1997). The information on
chronic ANS activation in HF with preserved left ventricular ejec-
tion fraction (i.e., diastolic HF) is very limited. In patients with
hypertension, ANS hyperactivity may contribute to the develop-
ment of left ventricular diastolic dysfunction and thus increase
HF risk (Hogg andMcMurray, 2005). In systolic HF, patients may
actually have decreased ANS neuronal density & function, result-
ing in decreased NE concentration within the cardiomyocytes, in
addition to decreased postsynaptic βAR density, due to depletion
of cardiac ANS neuronal NE stores and decreased NE presynap-
tic reuptake secondary to NE transporter downregulation (Regitz
et al., 1991; Backs et al., 2001).
With regards to the other major AR type expressed in the heart,
α1ARs inHFmay function in a compensatory fashion tomaintain
cardiac inotropy, but their involvement in cardiac pathophysi-
ology appears limited to situations of cardiac hypertrophy that
ultimately lead to HF (Knowlton et al., 1993). For instance, in the
presence of pressure overload, cardiac α1AARs get activated and
promote cardiomyocyte survival (i.e., block apoptosis), protect-
ing against adverse remodeling and decompensation to HF (Du
et al., 2006; Huang et al., 2007).
CONCLUSIONS/FUTURE PERSPECTIVES
A vast number of studies over the past few decades have estab-
lished the crucial role of activated ANS in the compensatory
response of the circulation to retain its hemodynamic stability
in the face of a cardiac insult, and when this fails, its exces-
sive activation that accelerates HF progression and poses severe
toxicity on the chronically failing heart. Additionally, the bene-
fits of β-blockers and other therapeutic modalities that mitigate
or protect the heart against this ANS hyperactivity are also well
established. Among the several basic research developments aim-
ing at reducing the activity and/or the detrimental effects of the
ANS on the failing heart are sympatholytic agents (α2AR ago-
nists), polymorphic variants of cardiac ARs that confer better
prognosis in HF or better responses to current HF treatments,
new sympathomimetics that seek to augment the function of the
seemingly “cardioprotective” β1AR while simultaneously block-
ing the “cardiotoxic” β1AR (e.g., clenbuterol), activation of the
cardiac parasympathetic nervous system, and, last but not least,
augmentation of cardiac βAR-dependent function without the
accompanying elevation of ANS activity/outflow. The latter is
pursued with the very promising GRK2 inhibition therapeutic
approach, which improves both cardiac adrenergic and inotropic
reserves, while keeping the ANS outflow in check by restoring
or augmenting central, cardiac and adrenal sympatho-inhibitory
α2AR function. Future studies will most certainly help ascertain
the magnitude of the therapeutic potential these ANS activity-
targeting approaches hold for the fight against HF and other
cardiovascular diseases.
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